|
|
|
| home > pmps > winter 2021 > overcoming the challenge of accurate supplier labelling |
|
|
 PUBLICATIONS |
Pharmaceutical Manufacturing and Packing Sourcer
|
|
Mergers and acquisitions are all too common for pharmaceutical manufacturers. While the combination of two companies has its benefits, it doesn’t come without growing pains and challenges. Take, for example, labelling. A merger can result in decentralised labelling processes with inherited home-grown systems and a new array of third-party suppliers, contract manufacturers, re-packagers, and re-labellers. It can also lead to expansion into new geographic markets; each with their own country-specific labelling requirements.
As growing pharma manufacturers work to address these challenges, the importance of label accuracy can’t be understated.
A decentralised approach to labelling makes achieving label accuracy and consistency a complex task that can be a major threat to profitability, drag down efficiency, reduce agility, and impact speed-to-market.
|
Read full article from PDF >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
Ken Moir, Vice President at NiceLabel, has over 25 years of experience as an international technology sales and marketing leader, and was a partner in two high-tech start-ups, as well as a member of the management team at Zebra Technologies. He has extensive international technology sales and marketing experience, specifically in the fields of product, channel, vertical, and alliance sales and marketing. Ken is an automatic identification and data capture (AIDC) industry veteran with diverse market and technology knowledge, including barcode, radio frequency identification (RFID), mobility, SAP, and label management solutions.
|
|
|
Ken Moir |
|
|
|
|
|
|
|
 |
News and Press Releases |
 |
Sanner consistently invests in own tool and mold making
Bensheim, Germany, February 3, 2021 – Sanner, manufacturer
of pharmaceutical primary packaging and medical technology products, is
investing in the expansion of its in-house tool and mold making. This
enables the company to ensure rapid delivery of standard products that
are in high demand especially in times of pandemic, such as desiccant
closures and nutritional supplements packaging. However, the investments
are also paying off in the development and implementation of new
products and will be consistently continued in 2021.
More info >> |
|
 |
White Papers |
 |
|
Backward Thinking: The Reverse Engineering of A Pressurized Metered Dose Inhaler
Development of a generic equivalent to a current marketed pressurized metered dose inhaler (pMDI) product brings immense challenges. Thorough analysis is critical to gain a comprehensive understanding of the physical attributes and pharmaceutical performance of the reference marketed product. Many factors need to be assessed, understood and combined in order to successfully develop a generic pMDI which will meet the regulatory and quality requirements as an equivalent product in the anticipated target market.
Significant information about the reference marketed product can be obtained from a thorough review of published literature, specifically the Summary of Product Characteristics (SPC) and Patient Information Leaflet (PIL). Additionally, baselining the reference marketed product for pharmaceutical performance offers a working target specification for in-vitro correlation. It will ensure the smoothest possible path to commercialization and maximize return on investment. In addition, baselining of the reference marketed product is done to understand batch-to-batch variability and product performance over the stated shelf life to establish targets for critical quality attributes (CQAs), which can be applied to the generic equivalent pMDI.
More info >> |
|
|
